Skip to main content

Human Complement Factor H-related 5/CFHR5 Alexa Fluor™ Plus 488-conjugated Antibody

R&D Systems, part of Bio-Techne | Catalog # AF3845AFP488

Catalog #
Availability
Size / Price
Qty
Loading...
AF3845AFP488-100UG

Key Product Details

Species Reactivity

Human

Applications

Western Blot, Immunoprecipitation

Label

Alexa Fluor Plus 488 (Excitation = 493 nm, Emission = 518 nm)

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human Complement Factor H-related 5/CFHR5

Specificity

Detects human Complement Factor H-related 5/CFHR5  in direct ELISAs and Western blots.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Applications

Application
Recommended Usage

Immunoprecipitation

Optimal dilution of this antibody should be experimentally determined.

Western Blot

Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Formulation

Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

Background: Complement Factor H-related 5/CFHR5

The human complement factor H protein family consists of the complement and immune regulators factor H, the factor H‑like protein 1 (FHL-1) and five factor H‑related proteins (FHR-1 to -5) (2). Members of this family are exclusively composed of individually folded protein domains, termed short consensus repeats (SCRs) or complement control modules. The genes of this family have been located in human chromosome 1q32, which is known as the regulator of complement activation (RCA) gene clusters (3). FHR-5 has been identified initially as a universal component of complement deposits (1), and detected in glomerular immune deposits (4). The pattern of deposits is similar to other complement components, suggesting that FHR-5 may play a role in complement activation and regulation. It is synthesized in the liver and consists of 9 SCRs. Its biological function is not understood fully. FHR-5 exhibits similar characteristics as those of factor H in heparin binding, CRP binding, and lipoprotein association (5). Weak factor I-dependent cofactor activity for C3b cleavage has also been observed (5).

References

  1. McRae, J. L. et al. (2001) J. Biol. Chem. 276:6747.
  2. Zipfel, P. F. et al. (2002) Biochem. Soc. Trans. 30:971.
  3. McRae, J. L. et al. (2002) Genetica. 114:157.
  4. Murphy, B. et al. (2002) Am. J. Kidney. Dis. 39:24.
  5. McRae, J. L. et al. (2005) J. Immunol. 174:6250.

Alternate Names

CFHL5, CFHR5, Complement Factor Hrelated 5, FHR5

Entrez Gene IDs

81494 (Human)

Gene Symbol

CFHR5

UniProt

Additional Complement Factor H-related 5/CFHR5 Products

Product Documents

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices


This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

For research use only

Loading...
Loading...
Loading...
Loading...